Oxid Med Cell Longev 2022 11;2022:3185320. Epub 2022 Jun 11.
Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan, 030001 Shanxi, China.
Objective: To compare the merits and demerits of PEG-IFN-2a and PEG-IFN-2b for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).
Methods: Clinical files from eighty-four CHB patients admitted to the Second Hospital of Shanxi Medical University between January 2018 and January 2019 were retrospectively analyzed and assigned to two groups: group 2a treated with PEG-IFN-2a and group 2b treated with PEG-IFN-2b. The clinical efficacy was compared between the above two arms, and the liver function (ALT, AST, HA, LN, and IV-C), HBV-DNA, HBsAg, HBeAg, and inflammatory factors (IFs, IL-1, IL-6, IL-8, and TNF-) were tested at 12 weeks (T1), 24 weeks (T2), and 48 weeks (T3). Read More